Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy

By sjmartinez • May 11, 2024

Kittipibul V, Vaduganathan M, Ikeaba U, Chiswell K, Butler J, DeVore AD, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Linganathan KK, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC, Greene SJ. Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy. JACC Heart Fail. 2024 Apr 6:S2213-1779(24)00268-3. doi: 10.1016/j.jchf.2024.04.003. Epub ahead of print. PMID: 38727651.

Tags: Cardiology/Epi, Cost, heart failure, Hospitalization, Publications, SGLT2 inhibitor

Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes[...]

Genetic Variants Associated with the Biochemical Response to Vitamin D3 in the Multi-Ethnic Study of Atherosclerosis

Best CM, Li X, Rotter JI, Prince DK, Hsu S, Hoofnagle AN, Siscovick D, Taylor KD, Williams K, Michos ED, Psaty BM, Shea S, Rice[...]

Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum

Shahid I, Khan MS, Butler J, Fonarow GC, Greene SJ. Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum.[...]